Genentech launches direct-to-patient program for flu drug Xofluza
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
Genentech Expands Xofluza® Access and Affordability for Upcoming Flu Season With Direct-to-Patient Launch
October 16, 2025 11:45 AM EDTGenentechs new program will provide access to Xofluza through select pharmacies with a $50 cash pay option, 70 percent lower than the list price
Direct-to-patient program focuses on same day delivery in select U.S. markets and improves affordability for patients who are underinsured, uninsured or self-pay
This program addresses the significant public health impact that flu continues to have on society; the overall flu burden during the 2024-25 season was the most severe in seven years
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of... More
